Research update: November 2026
Cagrilintide and eloralintide are two of the most closely watched compounds in amylin research. Both are long-acting amylin-pathway agonists, but they differ in receptor activity, clinical development, and the combinations being investigated alongside them.
The question that brings many readers here is straightforward: What can the available trial evidence establish? Eloralintide’s Phase 2 trial reported a larger mean weight reduction than the cagrilintide arm of REDEFINE 1. However, those were separate trials with different durations and analysis methods. These observations help researchers interpret study hypotheses, but cannot establish comparative superiority without a suitably designed head-to-head trial.
What Is the Amylin Pathway?
Amylin is a naturally occurring hormone involved in signaling fullness and regulating food intake. It works through receptors that include the calcitonin receptor and receptor activity-modifying proteins. Researchers are interested in how compounds acting on this pathway influence satiety, gastric emptying, and energy balance.
Amylin signaling is also being studied alongside incretin pathways. That is why several major clinical programs pair an amylin agonist with a GLP-1-based compound. The combination studies ask a different question from studies of either molecule alone.
What Is Cagrilintide?
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It activates receptors in the amylin and calcitonin receptor family and has been investigated as a standalone compound and in combination with semaglutide.
Its largest comparison data include a cagrilintide-only arm in the Phase 3 REDEFINE 1 study. That trial also included CagriSema, semaglutide alone, and placebo. The design gives researchers a way to examine the combination alongside its individual components within the same study.
What Is Eloralintide?
Eloralintide, developed by Eli Lilly, is a long-acting selective amylin receptor agonist with a preference for AMY1. Its more focused receptor profile has made it an important compound in research comparing different approaches to amylin signaling.
In a 48-week Phase 2 study, researchers evaluated several amounts and escalation schedules. The published trial included 263 adults with obesity or overweight and a weight-related condition, without type 2 diabetes. Lilly has since advanced eloralintide into the ENLIGHTEN Phase 3 development program.
Cagrilintide vs. Eloralintide at a Glance
| Feature | Cagrilintide | Eloralintide |
|---|---|---|
| Developer | Novo Nordisk | Eli Lilly |
| Receptor profile | Amylin and calcitonin receptor activity | Selective amylin receptor agonist with AMY1 preference |
| Combination program | CagriSema with semaglutide | EloraTZP with tirzepatide |
What Did the Monotherapy Studies Report?
In Lilly’s Phase 2 study, the eloralintide 9 mg group had a mean body-weight reduction of 20.1% at 48 weeks, compared with 0.4% for placebo, using the efficacy estimand.
In REDEFINE 1, the cagrilintide 2.4 mg arm had a mean reduction of 11.8% at 68 weeks, compared with 2.3% for placebo, using the trial-product estimand. The treatment-policy analysis reported 11.5% for cagrilintide and 3.0% for placebo.
The two cagrilintide figures describe the same study arm under different analysis methods. The trial-product analysis estimates outcomes under continued adherence. The treatment-policy analysis includes outcomes regardless of whether participants stayed on assigned treatment. Different trials, timelines, and analyses limit comparisons between the two compounds.
Sources:
Eloralintide Phase 2 publication ·
REDEFINE 1 publication ·
Novo Nordisk study results
EloraTZP vs. CagriSema: The Combination Studies
EloraTZP combines eloralintide with tirzepatide. In a 48-week Phase 2b study in adults with obesity or overweight and type 2 diabetes, Lilly reported a mean reduction of 23.3% for eloralintide 9 mg plus tirzepatide 15 mg, versus 14.8% for tirzepatide 15 mg alone, using the efficacy estimand. The comparison with tirzepatide alone was a secondary endpoint; the Phase 2b study used separate injections rather than the later coformulation. The Phase 3 AMPLIFY-2 study is comparing the coformulation with tirzepatide in adults with overweight or obesity and type 2 diabetes. The trial tracker listed AMPLIFY-2 as recruiting as of November 6, 2026. Trial recruitment is not a result.
Which amylin program looks stronger? There is no sound answer from combining isolated top-dose percentages. CagriSema and EloraTZP use different GLP-1/incretin partner compounds, study populations and analysis frameworks, so even their combination data are not a direct comparison of cagrilintide with eloralintide. Explore the dated eloralintide and EloraTZP trial index for the experimental designs and Xcel’s complete eloralintide research guide for the monotherapy evidence and uncertainties.
CagriSema combines cagrilintide with semaglutide. In the 68-week REDEFINE 1 study in adults without type 2 diabetes, CagriSema produced a mean reduction of 20.4%, compared with 3.0% for placebo, under the treatment-policy analysis.
These combination studies used different partner compounds and enrolled different populations. Lilly also reported gastrointestinal adverse events more frequently in the EloraTZP combination arms than with either component alone.
Read Lilly’s EloraTZP Phase 2b announcement
What Remains Unknown?
A direct head-to-head trial would be needed to compare the two molecules under the same conditions. Researchers also continue to examine long-term outcomes, tolerability, titration schedules, and how different receptor profiles translate into clinical results.
In the published eloralintide Phase 2 trial, reported nausea varied across groups: 64% in the 6 mg group, 33% in the 9 mg group and 14% with placebo. Fatigue was reported in 29%, 43% and 12%, respectively. These are results within one study, not a direct safety comparison with cagrilintide. Adverse events and discontinuations matter alongside efficacy results.
The Research Takeaway
Cagrilintide and eloralintide give researchers two different ways to investigate the amylin pathway. Eloralintide’s Phase 2 monotherapy results attracted attention for their magnitude, while cagrilintide has been studied in a large Phase 3 program that included a standalone arm. Their combination programs add another layer to the story, with important differences in study design and population.
For more on the amylin pathway, see our eloralintide research guide and eloralintide half-life explainer. Another amylin candidate is covered in the petrelintide research update, and the wider field is mapped in our obesity drug pipeline overview.
For a deeper review, see our petrelintide clinical evidence overview and discussion of eloralintide analytical testing.
Further Reading
All products supplied by Xcel Research LLC are chemical reference materials intended solely for in vitro laboratory research. They are not drugs, foods, dietary supplements, cosmetics, or medical devices, and have not been approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. These materials are not for human or veterinary use and may not be administered to humans or animals under any circumstances.